Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Journal of Clinical Lipidology

Volumn 9, Issue 6, 2015, Pages 758-769

  Moriarty, Patrick M ^a   Thompson, Paul D ^b   Cannon, Christopher P ^c,d   Guyton, John R ^e   Bergeron, Jean ^f   Zieve, Franklin J ^g   Bruckert, Eric ^h   Jacobson, Terry A ⁱ   Kopecky, Stephen L ^j   Baccara Dinet, Marie T ^k   Du, Yunling ^l   Pordy, Robert ^l   Gipe, Daniel A ^l  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f LAVAL UNIVERSITY   (Canada)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MAYO CLINIC   (United States)

^k SANOFI   (France)

^l REGENERON PHARMACEUTICALS INC   (United States)

more..

Author keywords

Clinical trials; Lipid lowering drugs; Lipoproteins; Monoclonal antibodies; PCSK9

Indexed keywords

ALANINE AMINOTRANSFERASE; ALIROCUMAB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CREATINE KINASE; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BACKACHE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RECHALLENGE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE FATIGUE; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL STIFFNESS; MYALGIA; MYOSITIS; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKELETAL MUSCLE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; SAFETY;

AZETIDINES; DOUBLE-BLIND METHOD; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SAFETY;

EID: 84947965019     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.08.006     Document Type: Article

References (30)

1. N.J. Stone, J. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 63 2013 2899 2934
2. T.A. Jacobson, M.K. Ito, K.C. Maki, and et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary J Clin Lipidol 8 2014 473 488
3. Cholesterol Treatment Trialists (CTT) Collaboration C. Baigent, L. Blackwell, J. Emberson, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
4. G.B. Mancini, S. Baker, J. Bergeron, and et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Proceedings of a Canadian Working Group Consensus Conference Can J Cardiol 27 2011 635 662
5. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Begaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
6. R.S. Rosenson, S.K. Baker, T.A. Jacobson, S.L. Kopecky, and B.A. Parker An assessment by the Statin Muscle Safety Task Force: 2014 update J Clin Lipidol 8 2014 S58 S71
7. J.R. Guyton, H.E. Bays, S.M. Grundy, T.A. Jacobson The National Lipid Association Statin Intolerance P An assessment by the Statin Intolerance Panel: 2014 update J Clin Lipidol 8 2014 S72 S81
8. E.S. Stroes, P.D. Thompson, A. Corsini, and et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Eur Heart J 36 2015 1012 1022
9. H.V. Ganga, H.B. Slim, and P.D. Thompson A systematic review of statin-induced muscle problems in clinical trials Am Heart J 168 2014 6 15
10. B.A. Parker, J.A. Capizzi, A.S. Grimaldi, and et al. Effect of statins on skeletal muscle function Circulation 127 2013 96 103
11. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
12. E.A. Stein, D. Gipe, J. Bergeron, and et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
13. E.M. Roth, J.M. McKenney, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
14. E.M. Roth, M.R. Taskinen, H.N. Ginsberg, and et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial Int J Cardiol 176 2014 55 61
15. J.G. Robinson, M. Farnier, M. Krempf, and et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1489 1499
16. G.G. Schwartz, L. Bessac, L.G. Berdan, and et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial Am Heart J 168 2014 682 689
17. C.P. Cannon, B. Cariou, D. Blom, and et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial Eur Heart J 36 2015 1186 1194
18. D.J. Kereiakes, J.G. Robinson, C.P. Cannon, and et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study Am Heart J 169 2015 906 915.e913
19. H. Bays, D. Gaudet, R. Weiss, and et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial J Clin Endocrinol Metab 100 2015 3140 3148
20. Z. Reiner, A.L. Catapano, G. De Backer, and et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
21. P.M. Moriarty, T.A. Jacobson, E. Bruckert, and et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial J Clin Lipidol 8 2014 554 561
22. Food and Drug Administration. Drug Approval Package. Zetia (ezetimibe) tablets, 2014. Food and Drug Administration, US.
23. O. Siddiqui, H.M. Hung, and R. O'Neill MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets J Biopharm Stat 19 2009 227 246
24. National Research Council (US) Panel on Handling Missing Data in Clinical Trials. The Prevention and Treatment of Missing Data in Clinical Trials 2010 National Academies Press Washington (DC)
25. G. Chodick, V. Shalev, Y. Gerber, and et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel Clin Ther 30 2008 2167 2179
26. W.M. Mampuya, D. Frid, M. Rocco, and et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience Am Heart J 166 2013 597 603
27. G.D. Norata, C.M. Ballantyne, and A.L. Catapano New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs Eur Heart J 34 2013 1783 1789
28. E. Stroes, D. Colquhoun, D. Sullivan, and et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
29. A. Pandor, R.M. Ara, I. Tumur, and et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials J Intern Med 265 2009 568 580
30. J.W. Nawrocki, S.R. Weiss, M.H. Davidson, and et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor Arterioscler Thromb Vasc Biol 15 1995 678 682